TITLE

COMPANY SPOTLIGHT - Onyx Pharmaceuticals, Inc

PUB. DATE
November 2009
SOURCE
PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p24
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article presents a company profile for Onyx Pharmaceuticals Inc., a U.S.-based biopharmaceutical company engaged in research and development of drugs for cancer treatment. Nexavar or sorafenib, a kinase and angiogenesis inhibitor for targeting signal pathways for the proliferation of cancer cells, is one of the company's products. A strengths, opportunities, weaknesses and threats (SWOT) analysis for the company is also given.
ACCESSION #
45024169

 

Related Articles

  • Precious Mettle. Comer, Benjamin // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28 

    The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds,...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p3 

    The article reports developments in the pharmaceutical industry worldwide. AstraZeneca PLC has continued to use drug development alliances to help restock a pipeline that has been hit by several recent late-stage product setbacks. The Nexavar tablets of Bayer AG and Onyx Pharmaceuticals Inc....

  • Pharmaceutical sector sees flurry of acquisitions.  // Chain Drug Review;9/9/2013, Vol. 35 Issue 14, p13 

    The article offers information on several acquisitions in the U.S. pharmaceutical industry including the purchase of Onyx Pharmaceuticals Inc. by Amgen Inc., acquisition of Hi-Tech Pharmacal Co. by Akorn Inc. and purchase of Amplimmune Inc. by AstraZeneca PLC.

  • EARNINGS ROUNDUP.  // BioWorld Today;5/8/2008, Vol. 19 Issue 90, p2 

    This section offers news briefs concerning the U.S. biopharmaceutical industry. Emergent BioSolutions, Inc. has posted increased revenues and a net income of $7 million or 24 cents per share for the first quarter of 2008. The total sales generated by Onyx Pharmaceuticals, Inc. for its Nexavar...

  • Onyx Sues Partner Bayer over Nexavar Spinoff.  // BioWorld Today;5/19/2009, Vol. 20 Issue 95, p2 

    The article reports on a lawsuit filed by Onyx Pharmaceuticals Inc. against Bayer Corp. accusing it of developing a slightly modified version of the drug Nexavar to compete against the product, which they jointly own. The lawsuit asserts the rights of Onyx to Phase II anticancer compound...

  • RESEARCH & TECHNOLOGY.  // MondayMorning;8/2/2010, Vol. 18 Issue 29, p4 

    The article presents news brief related to the drug industry. Allos Therapeutics Inc. reports that its lung-cancer drug Folotyn increased survival of patients, however, the lower sales raised concern about the marketing opportunity. A study revealed that prostate cancer vaccine Provenge...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Sep2006, Vol. 5 Issue 9, p4 

    The article reports developments in the pharmaceutical industry worldwide from July 15, 2005 to August 14, 2006. The drugs for the treatment of kidney cancer and renal cell carcinoma from Pfizer Inc. and Bayer AG and Onyx Pharmaceuticals Inc. have gained approval to be sold in Europe. Pfizer's...

  • Onyx Raises $185 Million On Nexavar Data In Liver Cancer. Morrison, Trista // BioWorld Today;6/22/2007, Vol. 18 Issue 121, p1 

    The article reports that Onyx Pharmaceuticals Inc. is raising $185 million in response to the positive prospects of its kidney cancer drug Nexavar. Onyx will be offering 6.6 million shares at $28 per share in a transaction managed and underwritten by Morgan Stanley & Co. Inc. and Merrill Lynch &...

  • Onyx's Shares Plummeted on NSCLC Data.  // Bioworld Week;2/25/2008, Vol. 16 Issue 8, p2 

    The article reports on the 26.4% drop of shares of Emeryville, California-based Onyx Pharmaceuticals Inc. due to the termination of the Phase III study of Nexavar, a non-small-cell lung cancer drug. It notes that the termination of the trial is associated with the lack of efficacy of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics